Assessment | Time of data collection | ||
---|---|---|---|
Baseline (enrollment) | Follow-up (quarterlya) | Death or study discontinuation | |
Informed consent | X | ||
Demographic data | X | ||
Functional/performance status | X | X | X |
Cardiovascular risk factors | X | ||
Other relevant medical history | X | ||
Selected concomitant medications | Xb | X | X |
Selected laboratory tests | X | X | X |
Breast cancer–specific cancer history | Xc | ||
Prior cancer treatment history | X | ||
Healthcare resource utilization | X | X | X |
Healthcare provider type | X | ||
Insurance coverage and provider | X | X | X |
PROsd | X | X | Xe |
Tissue and blood samplesf | X | X | |
Disease statusg | X | X | |
Chemotherapy treatment status | X | X | |
Interval surgical history | X | X | |
Interval radiotherapy history | X | X | |
Interval hormonal therapy history | X | X | |
Protocol-specified AEsh | X | X | |
Study discontinuation reason (including death) | X |